ASND vs. INSM: Ascendis Pharma vs. Insmed Stock Comparison
How do Ascendis Pharma (ASND) and Insmed (INSM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Ascendis Pharma (ASND) and Insmed (INSM) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ASND | INSM |
|---|---|---|
| Name | Ascendis Pharma A/S | Insmed Incorporated |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.90 billion USD | 25.10 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 28, 2015 | June 1, 2000 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ASND | INSM |
|---|---|---|
| Total Return (1Y) | 29.46% | -39.17% |
| Total Return (3Y, Annualized) | 40.62% | 70.17% |
| Total Return (5Y, Annualized) | 10.03% | 28.96% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ASND | INSM |
|---|---|---|
| Volatility (1Y, Annualized) | 38.62% | 63.09% |
| Beta (5Y) | 0.38 | 0.80 |
| Max Drawdown (5Y) | -55.93% | -56.54% |
| Avg. Volume (3M) | 698.39K | 2.76M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ASND | INSM |
|---|---|---|
| Sharpe Ratio (1Y) | 0.65 | -0.69 |
| Sortino Ratio (1Y) | 0.99 | -1.04 |
Profitability
ROE (TTM)
Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
118.78%
- ASND
- 118.78%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-72.45%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- INSM
- -72.45%
- Min
- -167.77%
Net Margin (TTM)
Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Ascendis Pharma (ASND) reports 70.85%, ranking against industry peers normally.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
70.85%
- ASND
- 70.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- INSM
- -39.85%
Operating Margin (TTM)
Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Ascendis Pharma (ASND) reports 64.98%, ranking against industry peers normally.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
64.98%
- Max
- 83.12%
- ASND
- 64.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-15.60%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- INSM
- -15.60%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ASND | INSM |
|---|---|---|
| ROE (TTM) | 118.78% | -72.45% |
| ROA (TTM) | 9.58% | -17.25% |
| Net Margin (TTM) | 70.85% | -39.85% |
| Operating Margin (TTM) | 64.98% | -15.60% |
| Gross Margin (TTM) | 91.30% | 84.40% |
Growth
Revenue Growth
Both Ascendis Pharma (ASND) at 98.03% and Insmed (INSM) at 66.73% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.
EPS Growth
Neither Ascendis Pharma (ASND) nor Insmed (INSM) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ASND | INSM |
|---|---|---|
| Revenue Growth (YoY) | 98.03% | 66.73% |
| Revenue Growth (3Y CAGR) | 141.43% | 35.20% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Ascendis Pharma (ASND) at 2.99 and Insmed (INSM) at 2.86 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ASND
- 2.99
- Q1
- 2.47
- Min
- 0.10
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INSM
- 2.86
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Ascendis Pharma (ASND) at 0.31 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- ASND
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 1.42
- INSM
- 1.01
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ASND | INSM |
|---|---|---|
| Current Ratio (MRQ) | 2.99 | 2.86 |
| Debt / Equity (MRQ) | 0.31 | 1.01 |
| Net Debt / EBITDA | -1.37 | -- |
Dividends
Dividend Yield (TTM)
Neither Ascendis Pharma (ASND) nor Insmed (INSM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Ascendis Pharma (ASND) nor Insmed (INSM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ASND | INSM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.68
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ASND
- 19.68
- Q1
- 13.30
- Min
- 0.07
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- INSM
- --
P/S Ratio (TTM)
On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Insmed (INSM) at 16.52 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.14
- Max
- 58.18
- Q3
- 25.77
- ASND
- 16.14
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.52
- Max
- 58.18
- Q3
- 25.77
- INSM
- 16.52
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Ascendis Pharma (ASND) at 10.45 sits in the upper P/B ratio quartile, and Insmed (INSM) at 34.55 prices even higher, above its industry range.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.45
- Max
- 13.53
- ASND
- 10.45
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.55
- INSM
- 34.55
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ASND | INSM |
|---|---|---|
| P/E Ratio (TTM) | 19.68 | -- |
| P/S Ratio (TTM) | 16.14 | 16.52 |
| P/B Ratio (MRQ) | 10.45 | 34.55 |
| Free Cash Flow Yield (TTM) | 0.08% | -1.82% |